Interpace Diagnostics Announces Receipt of Letter From Nasdaq Confirming Compliance With Minimum Closing Bid ... - GlobeNewswire (press release)

Interpace Diagnostics Announces Receipt of Letter From Nasdaq Confirming Compliance With Minimum Closing Bid ... GlobeNewswire (press release) The Company currently has three commercialized molecular tests; PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation ... and more »

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2enmJ6Y
via IFTTT